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Abstract: Although the main biological hypothesis on the pathophysiology of obsessive-compulsive 
disorder (OCD) is centered on the serotonin system, indications are available that other 
neurotransmitters, and even second messengers, particularly the cyclic adenosine monophosphate 
(cAMP) signaling, may be involved, though effective data are few. Therefore, the aim of the 
present study was to evaluate and compare the basal and isoprenaline (ISO)-stimulated velocity 
of adenylate-cyclase (AC) in human platelet membranes of patients with OCD and healthy 
control subjects. The results showed that the basal and ISO-stimulated AC activity, as well as 
the dose-response curves of ISO by using agonist concentrations ranging between 0.1 nM and 
10 µM, were not different in the two groups. However, OCD patients showed lower EC50 and 
higher Emax values than healthy subjects. These findings suggest the presence of supersensitive 
β-adrenergic receptors in platelets of OCD patients.
Keywords: obsessive-compulsive disorder, norepinephrine, second messengers, adenylate-
cyclase, platelets, isoprenaline, β-adrenergic receptors
Introduction
The most consistent hypothesis on the pathophysiology of obsessive-compulsive 
disorder (OCD) is focused on the serotonin (5-HT) system and, to a lesser extent, on 
dopamine (DA).1 However, few indications are available on the involvement of other 
neurotransmitters, such as norepinephrine (NE), peptides and, more recently, glutam-
mate.2–4 For NE, decreased levels of tiramine, a precursor of catecholamines, and of 
homovallinic acid, one of their metabolites, in the cerebrospinal fluid of OCD patients 
have been reported.5 Other support for a role of NE in OCD has been provided by the 
blunted growth hormone response to clonidine, an α2-adrenoreceptor antagonist, which 
would suggest hypersensitive presynaptic or hyposensitive postsynaptic α2 receptors,6 
but a negative finding has also been reported.2 Similar controversies are present in the 
literature on the direct evaluation of the binding parameters of α2-adrenoreceptors in 
platelets. In fact, when labeled by [3H]rauwolscine, they showed a similar density in 
OCD patients and control subjects,7 while [3H]clonidine revealed a greater density 
of α2-adrenoreceptors in OCD patients.2 The possible role of α2-adrenoreceptors is 
indirectly supported by the evidence that mirtazapine, an α2-adrenoreceptors antagonist, 
may reduce the onset of citalopram response in OCD patients.8
Blood platelets represent a reliable, peripheral model of presynaptic serotonergic 
neurons; in particular, they possess a 5-HT reuptake transporter similar to that present in 
the brain which has been deeply investigated in different psychiatric disorders including Neuropsychiatric Disease and Treatment 2009:5 364
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OCD.9–10 Besides the 5-HT transporter, platelets carry 
5-HT1A and 5-HT2 receptors, but also structures belonging 
to the catecholamine systems, such as the DA transporter and 
α- and β-adrenergic receptors.11 More recently, much interest 
has been devoted to intracellular mechanisms following 
receptor activation and there is a preliminary evidence for 
the involvement of cyclic adenosine monophosphate (cAMP) 
signaling in OCD, as shown by the lower protein kinase A 
(PKA) activity.12–13
In the present study, we aimed to explore and compare 
the basal adenylate cyclase (AC) activity in platelets of 
OCD patients and healthy control subjects, and that after 
stimulation by isoprenaline (ISO), a synthetic catecholamine 
which behaves as a β1-/β2-adrenergic receptor agonist, in both 




Twenty patients (10 men and 10 women, aged between 22 and 
31 years; mean ± SD: 24.1 ± 6.5), recruited at the outpatient 
unit of the “Clinica Psichiatrica, Dipartimento di Psichiatria, 
Neurobiologia, Farmacologia e Biotecnologie” at Pisa 
University, were included in the study. All met DSM IV-TR 
criteria for OCD, were not currently depressed, or had any 
history of mood disorders or any other comorbid conditions. 
Diagnoses were made by experienced psychiatrists, following 
the Structured Clinical Interview for DSM IV (SCID).14 No 
patients had ever taken psychotropic drugs in the past, except 
three who had taken benzodiazepines 1 year previously and 
one who had undergone supporting psychotherapy.
The subjects’ age (mean ± SD) at the onset of OC 
symptoms was 17 ± 5 years and the duration (mean ± SD) 
of the disorder was 5 ± 1 years.
The severity of OC symptoms was evaluated by means of 
the Yale Brown Obsessive-Compulsive Scale (Y-BOCS).15 
The total score (mean ± SD) was 26.4 ± 6.3 (range: 25 to 
40); the obsession subtotal score (mean ± SD) was 14.2 ± 4.5 
(range: 13 to 20); the compulsion subtotal score (mean ± SD) 
was 14.5 ± 4.9 (range: 12 to 20). The most commonly 
reported obsessions by the Y-BOCS Check-List were 
“contamination” (66.7%), “order and symmetry” (25.5%) and 
“others” (23.3%) comprising the need to remember certain 
things, the fear of saying certain things, the fear of being 
inexact, intrusive images, meaningless sounds or words or 
musical themes, fortunate/unfortunate numbers, and mean-
ingful colors. The most common compulsions were cleaning 
(53.3%), checking (53.3%), and repetition (53.3%). The 
degree of insight (mean ± SD) was 1.5 ± 1.5 (range: 0 to 4). 
Eight patients only had one obsession and/or compulsion, 
while the remaining 12 had more than one.
The severity of depression was rated by means of the 
Hamilton Rating Scale for depression (HRSD):16 the total 
score (mean ± SD) was 4 ± 1 and 3 ± 2 in, respectively, OCD 
patients and healthy controls.
Twenty healthy volunteers (10 men and 10 women, aged 
between 21 and 32 years, mean age ± SD: 24.2 ± 7.1) were 
selected for this study according to the following criteria: all 
subjects were without familiar or personal history of major 
psychiatric disorders, as assessed by the SCID, and had no 
current medical complaints and were physically healthy, as 
ascertained by their medical history and physical examination. 
No woman of both groups took contraceptive pills.
All subjects gave their written informed consent to 
participate in the study which was approved by the Ethics 
Committee at Pisa University.
chemicals
The radio-labelled compounds [32P]α-ATP (specific activity: 
30 Ci/mmol) and [3H] cAMP (specific activity: 27 Ci/mmol) 
were purchased from Perkin Elmer Life Science (Boston, MA, 
USA). Creatine kinase and creatine phosphate were obtained 
from Roche Molecular Biochemicals (Mannheim, Germany). 
All other reagents were from Sigma-Aldrich Chemical Co. 
(Milan, Italy) and of the highest grade available.
Methods
Thirty mL of blood were collected from fasting subjects 
between 8.00 and 10.00 am to avoid circadian rhythm 
interference. Samples were immediately put into Falcon 
tubes containing sodium citrate anticoagulant (1:6 dilution), 
composed by 2.2% sodium citrate, 1.2% citric acid, and 
gently mixed. Platelet-rich plasma (PRP) was obtained by 
blood low-speed centrifugation at 200 × g for 20 min at room 
temperature. The PRP was then centrifuged at 2000 × g for 
15 min at room temperature to precipitate platelets.
Adenylate cyclase assay
Platelets were washed once in 40 to 50 mL isotonic solution, 
0.9% NaCl, by centrifugation at 15,000 × g for 15 min at 4 °C. 
The resulting pellet was resuspended in a strongly hypotonic 
buffer containing 5 mM Hepes-NaOH, pH 7.4 at 25 °C, 1 mM 
EGTA and protease inhibitors (bacitracine 20 mg/100 mL; 
benzamidine 16 mg/100 mL, soybean trypsine inhibitor, 
2 mg/100 mL). Samples, kept on ice, were then homogenized 
by ultraturrax for 5 to 10 sec. After a 10- to 15-min incubation Neuropsychiatric Disease and Treatment 2009:5 365
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at 0 °C to remove endogenous compounds, samples were 
then centrifuged at 40,000 × g at 4 °C for 15 min. The final 
pellet was frozen in liquid nitrogen and stored until assay, 
performed within no more than 2 weeks. On the day of assay, 
membrane pellets were thawed and suspended in 10 mM 
Hepes buffer pH 7.4, containing 1 mM EGTA, to obtain a 
protein concentration of about 0.8 to 1.8 mg/mL: protein 
estimation was performed by means of the Bradford Bio-Rad 
kit,17 using γ-globulin as the standard. AC activity was 
measured in the reaction mixture, as described previously,18 
with slight modifications, such as the presence in the mix 
buffer of 0.33 mM EGTA, 0.005 mM pargyline and the use 
of GTP at the concentration of 0.01 mM.
Basal enzyme activity was also evaluated in the absence 
or presence of various concentrations (0.1 nM to 10 µM) 
(-)ISO. Some experiments were performed by adding the 
β antagonist propranolol (1 µM) and the α2 antagonist 
rauwolscine (10 µM). The reaction was started by the addi-
tion of 50 µL of membrane suspension and carried out by 
incubating samples for 15 min at 30 °C in a final assay volume 
of 150 µL. [32P]α-AMPc and [3H]AMPc were further purified 
through a double-step Dowex-Alumina chromatography.13
Data analysis
All experiments performed herein were carried out in dupli-
cate and presented as mean ± SEM. Statistical significance 
was preset at p = 0.05. Data analysis and statistics were per-
formed by GraphPad Software Inc., version 3.00, San Diego, 
CA, USA. The equation of Salomon12 was used to evaluate 
AC activity (pmol cAMP/min/mg protein). Concentration-
response curves of ISO on basal AC were analyzed in order 
to estimate EC50 (potency, concentration of drug causing 
50% of the maximal effect on enzyme activity, nM) and Emax, 
(efficacy, maximal inhibition, %) values. Data were shown as 
percentage (%) of basal AC activity in the presence of ISO 
vs basal AC activity without the agonist (considered to be 
100%). Two-tailed paired (within group) or unpaired t-tests 
(between group) were used to compare platelet AC velocities 
or ISO dose-response parameters in the two groups.
Results
As shown in Table 1, the platelet basal AC activity was 
similar in OCD patients and healthy subjects. The addition of 
10 µM ISO enhanced significantly (p  0.05) platelet basal 
AC in both groups, without intergroup differences.
The different concentrations of ISO led to dose-response 
curves with EC50 and Emax values (mean ± SEM), different 
in the two groups: OCD patients showed significantly lower 
(t = 4.78, p = 0.01) mean EC50 and higher (t = 6.46, p = 0.01) 
mean Emax than healthy subjects (Table 2, Figure 1).
In previous work, carried out in intact human platelets, the 
ISO stimulation was generally determined in the presence of 
the α-adrenergic antagonist phentolamine to avoid platelet α2 
inhibition of AC at the tested agonist concentrations.19–21 In 
the present study, we observed a stimulatory response after 
ISO in all subjects even without α-antagonists. Figure 2 shows 
the dose-response curves of ISO alone and in the presence of 
10 µM rauwolscine, 1 µM propranolol, and both antagonists. 
The addition of rauwolscine provoked a small leftward shift 
of the curve, whereas the addition of propranolol, a β-blocker, 
abolished the stimulation and revealed a weak ISO-mediated 
inhibition of AC at its higher concentrations (1 to 10 µM). The 
concomitant addition of ISO, rauwolscine and propranolol 
led to a partial AC stimulation by ISO (EC50 and Emax of 
about 2.5 µM and 25%, respectively), while displaying a 
dose-response curve shifted towards the right.
In the presence of rauwolscine the ISO EC50 (mean ± SEM, 
n = 3) was 68.67 ± 26.91 nM and the Emax was 161.3 ± 8.57%. 
In the same experiments without rauwolscine, the ISO EC50 
(mean ± SEM, n = 3) was 88.33 ± 16.59 nM and the Emax 
147.7 ± 1.45%, not statistically different.
No correlation between biochemical parameters and 
clinical characteristics of the disorder was detected.
Discussion
The main findings of the present study were the following. 
First, we did not detect any difference in the basal AC activity 
Table 1 Basal and 10 µM isO-stimulated adenylate cyclase activity 
in platelet membranes from healthy subjects and OcD patients
Basal AC + ISO 10 µM
healthy subjects 14.00 ± 1.72 20.61 ± 2.50
OcD patients 13.60 ± 1.59 22.99 ± 3.48
Note: Data are presented as mean ± seM of n experiments each performed in 
duplicate.
Abbreviation: isO, isoprenaline.
Table 2 isO stimulation parameters measured in platelet 
membranes of healthy subjects and OcD patients
EC50 (nM) Emax (%)
healthy subjects 85.62 ± 18.82 151.70 ± 4.40
OcD patients 53.80 ± 23.26* 177.40 ± 9.51**
Notes: Data are presented as mean ± seM of 3 experiments each performed in 
duplicate.
*significant, t = 4.78, p = 0.01.
**significant, t = 6.46, p = 0.01.
Abbreviation: isO, isoprenaline.Neuropsychiatric Disease and Treatment 2009:5 366
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in platelet membranes of healthy subjects and OCD patients. 
The addition of 10 µM ISO to platelet membranes provoked 
a significant stimulation of the enzyme activity of the same 
magnitude in the two groups. When different concentrations 
of ISO were used, the dose-response curve showed a signifi-
cant decrease of the agonist EC50 and increase of Emax values 
in OCD patients, as compared with those of control subjects. 
The β-blocking compound (-)propranolol (1 µM) removed 
the ISO response, while revealing also a weak degree of inhi-
bition of AC at ISO concentrations 1 µM. In the presence 
of rauwolscine 10 µM, the ISO-stimulating response showed 
a shift of EC50 of about 1.5-fold. Previous studies in whole 
platelets showed that the presence of α-antagonists, such as 
phentolamine, can provoke the ISO-stimulating response.22 In 
our study, carried out in platelets membranes and in the pres-
ence of an optimal mix of reaction, we observed a significant 
stimulation via ISO, even in the absence of the α-antagonists. 
OCD patients and healthy controls were compared by using a 
lower range of concentration of the agonist and by eliminat-
ing the highest concentrations of ISO, when the activation 
of the inhibiting α2 receptors was detected. These findings 
suggests that, under our experimental conditions, there is 
an inhibitory component of ISO effect on platelet AC, due 
to the agonist interaction with α2-receptors, at its higher 
concentrations (1 µM).
These results suggest the presence of a condition of 
supersensitive β-receptors in platelets of OCD patients that, 
perhaps, could reflect (or provoke) alterations of the intra-
cellular signaling system mediated by the cAMP and of the 
related kinases. This is consistent with recent findings show-
ing a decreased activity of PKA in OCD patients.23
The concomitant evidence of increased PKC activity, 
triggered by the hydrolysis of phosphatidylinositol (4,5)-
bisphosphate (PI), in patients suggest that, perhaps, this 
condition might be characterized by an imbalance between 
the two main second-messenger pathways (cAMP and PI), 
with a prevalence of the second, given the cross-talk between 
the two main second messengers at the level of different 
effectors.12
In conclusion, the results of the present study suggest that 
abnormal second messenger pathways in OCD may be also 
related to cathecolamine system disturbances, which might 
open new therapeutic strategies especially in resistant patients 
who do not respond to serotonergic medications.
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Figure 1 isoprenaline dose-response curve in one OcD patient and control subject.
Abbreviation: isO, isoprenaline
Figure 2 Dose-response curve of isoprenaline alone and in the presence of rauwolscine, 
propanolol and both the compounds.
Abbreviation: isO, isoprenaline
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